Idiopathic pulmonary fibrosis (IPF) is a highly heterogeneous, unpredictable and ultimately
lethal chronic lung disease. Over the last decade, two anti-fibrotic agents have been shown …

This is a time of substantial progress in the evaluation and care of patients with idiopathic
pulmonary fibrosis (IPF). In addition to the approval and widespread availability of the first …

Molecular biomarkers are highly desired in idiopathic pulmonary fibrosis (IPF), where they
hold the potential to elucidate underlying disease mechanisms, accelerated drug …

Idiopathic pulmonary fibrosis (IPF) remains a disease with poor survival. The pathogenesis
is complex and encompasses multiple molecular pathways. The first-generation antifibrotics …

Idiopathic pulmonary fibrosis (IPF), the most lethal form of interstitial pneumonia of unknown
cause, is associated with a specific radiological and histopathological pattern (the so-called …

Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease. Recent studies have
identified the key role of crosstalk between dysregulated epithelial cells, mesenchymal …

Fibrosis is the concluding pathological outcome and major cause of morbidity and mortality
in a number of common chronic inflammatory, immune-mediated and metabolic diseases …

Idiopathic pulmonary fibrosis (IPF), the most common form of fibrosing idiopathic interstitial
pneumonia, is an inexorably progressive disease with a 5-year survival of~ 20%. In the last …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive diffuse parenchymal lung
disease of unknown origin, with a mortality rate exceeding that of many cancers. The …

Pulmonary fibrosis is a pathologic process associated with scarring of the lung interstitium.
Interstitial lung diseases (ILDs) encompass a large and heterogenous group of disorders, a …